Pimavanserin

CHEMBL2111101 Phase 4 Disetujui Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

427.6 g/mol

LogP

4.5

Phase

4

Used to treat hallucinations and delusions that occur in people with Parkinson's disease psychosis by selectively blocking certain serotonin receptors in the brain without affecting dopamine pathways. This targeted approach makes it particularly suitable for Parkinson's patients who cannot tolerate medications that block dopamine.

Berat Molekul

427,6000 g/mol

LogP

4,50

TPSA

44,80 Å²

Lipinski RO5

Lulus

Area Terapeutik

Alzheimer's Disease Parkinson's Disease Schizophrenia Insomnia Major Depressive Disorder

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Struktur 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1

InChI

InChI=1S/C25H34FN3O2/c1-19(2)18-31-24-10-6-20(7-11-24)16-27-25(30)29(23-12-14-28(3)15-13-23)17-21-4-8-22(26)9-5-21/h4-11,19,23H,12-18H2,1-3H3,(H,27,30)

Molecular Formula

C25H34FN3O2

HBD / HBA

1 / 4

Ikatan yang Dapat Dirotasi

8

Atom Berat

31

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

Used to treat hallucinations and delusions that occur in people with Parkinson's disease psychosis by selectively blocking certain serotonin receptors in the brain without affecting dopamine pathways. This targeted approach makes it particularly suitable for Parkinson's patients who cannot tolerate medications that block dopamine.

Yes, Pimavanserin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2111101. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 10071196. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Mencari informasi yang ramah bagi pasien?

Pimavanserin di PillFYI

Struktur

Data Cepat

Rumus: C25H34FN3O2
Sinonim: 1

Tautan Eksternal

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.